ESMO 2019: Breast and ovarian cancer drug outperforms targeted hormone therapy in some men

September 30, 2019

A drug used for breast and ovarian cancer is more effective than modern targeted hormone treatments at slowing progression and improving survival in some men with advanced prostate cancer, phase III clinical trial findings reveal.

The PROfound trial compared the genetically targeted cancer drug olaparib - already licensed for women with breast and ovarian cancer who have BRCA mutations - with the modern hormone treatments abiraterone and enzalutamide in patients who had advanced prostate cancer and faulty DNA repair genes.

The study, led by researchers at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, and Northwestern University, Chicago, USA, showed that treatment with olaparib in men withfaulty DNA repair genes significantly delayed disease progression by about four months compared with enzalutamide and abiraterone. Treatment with olaparib resulted in a 66 per cent greater delay in disease progression.

The trial selected men who had been unsuccessfully treated with a modern hormone therapy and whose tumours had defects in at least one of 15 pre-selected DNA repair genes, including BRCA1 and BRCA2. The research follows on from an earlier trial, led by The Institute of Cancer Research (ICR) and The Royal Marsden, which found that around 80 per cent of men whose tumours had faults in the BRCA genes responded to olaparib.

For patients with genetic alterations in BRCA1, BRCA2 or ATM, the PROfound trial showed that the median length of time before the cancer got worse, known as progression-free survival, was 7.4 months with olaparib, compared to 3.6 months with targeted hormonal treatment. Additionally, median overall survival was 18.5 months with olaparib compared with 15 months with targeted hormonal treatment. However, researchers pointed out that the patients on the study needed longer follow-up to show a survival improvement conclusively.

The results were presented at the European Society for Medical Oncology (ESMO) Congress 2019 and demonstrate the efficacy of olaparib in men with advanced prostate cancer and gene defects involved in a cell's ability to repair its DNA.

The PROfound findings also showed that, like breast and lung cancers, prostate cancer has different disease sub-types. As a consequence, this phase III trial is the first to highlight the importance of genomic testing in prostate cancer patients, and the need to identify different patient groups and tailor treatment for them.

The researchers did find that adverse effects were more common with olaparib than with abiraterone or enzalutamide - 16.4 per cent of patients discontinued olaparib because of adverse events, compared with 8.5 per cent with the modern hormone-based drugs. However, the duration of treatment with olaparib was twice as long.

The ICR discovered how to genetically target olaparib and worked with The Royal Marsden to develop the drug in clinical trials. The ICR also discovered, and developed with The Royal Marsden, abiraterone - which has transformed treatment for men with prostate cancer.

Professor Johann de Bono, Regius Professor of Cancer Research at The Institute of Cancer Research, London, and Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, who co-led the PROfound trial, said:

"Our clinical trial shows that olaparib, a pill without the side-effects of chemotherapy, is able to target an Achilles' heel in cancer cells. Olaparib is able to kill cancer cells with faulty DNA repair genes while sparing normal cells.

"This study is a powerful demonstration of the potential of precision medicine to transform the landscape for patients with the commonest of male cancers. I hope that within the next couple of years, olaparib will become the first precision medicine to become available as a standard treatment for men with prostate cancer.

"Our findings also have wider implications - in showing that prostate cancer, like many other cancer types, is really a range of sub-types of disease identifiable by their different arrays of genetic faults. It's essential that we become smarter in the way we treat prostate cancer, so that every man gets the treatment that will be of greatest benefit for them."

Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said:

"It was scientists at the ICR who first discovered how to target olaparib at cancer's genetic weaknesses.Olaparib has already improved and extended the lives of women with ovarian and breast cancer and it's hugely positive to now see the results of this trial paving the way for olaparib to become an innovative new treatment for prostate cancer.

"It's only through discovering innovative treatments like olaparib that we're going to give doctors the treatment options they need to combat cancer's ability to evolve resistance and evade treatment. Our new Centre for Cancer Drug Discovery, which we hope to finish next year, will help us discover the drugs needed to overcome cancer evolution and turn cancer into a long-term manageable disease."
The PROfound trial was funded by AstraZeneca and the principal investigators were Professor Johann de Bono, from the ICR and The Royal Marsden, and Professor Maha Hussain, from theRobert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, USA.

Notes to editors

For more information please contact Diana Cano Bordajandi in the ICR press office on 020 7153 5021 or For enquiries out of hours, please call 07595 963 613.

The Institute of Cancer Research, London, is one of the world's most influential cancer research organisations.

Scientists and clinicians at The Institute of Cancer Research (ICR) are working every day to make a real impact on cancer patients' lives. Through its unique partnership with The Royal Marsden NHS Foundation Trust and 'bench-to-bedside' approach, the ICR is able to create and deliver results in a way that other institutions cannot. Together the two organisations are rated in the top four centres for cancer research and treatment globally.

The ICR has an outstanding record of achievement dating back more than 100 years. It provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease. Today it is a world leader at identifying cancer-related genes and discovering new targeted drugs for personalised cancer treatment.

A college of the University of London, the ICR is the UK's top-ranked academic institution for research quality, and provides postgraduate higher education of international distinction. It has charitable status and relies on support from partner organisations, charities and the general public.

The ICR's mission is to make the discoveries that defeat cancer.

For more information visit

Institute of Cancer Research

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to